Influenza Clinical Trial
— DOCACUPOfficial title:
Digital Online Consultations - Effects on Antibiotic Prescribing and Health Care Utilization in Primary Care
NCT number | NCT03474887 |
Other study ID # | 2017/948 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | March 30, 2018 |
Est. completion date | December 20, 2021 |
Verified date | January 2022 |
Source | Region Skane |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
BACKGROUND/SIGNIFICANCE: With developments in mobile health and the abundance of smartphones, online consultations have emerged as a popular form of primary care in Sweden. Controversy exists regarding diagnostic accuracy, appropriate prescription of antibiotics, and effects on care-seeking patient behavior following implementation of online consultations. As empirical research is lacking, the investigators seek to evaluate online primary care consultations compared to physical consultations with regards to non-inferiority of antibiotic prescription for chief complaint of sore throat. METHODS: Medical record data is used to identify patients with a chief complaint of sore throat, cough/common cold/influenza, or dysuria after choosing online (DIGI) or physical (PHYSI) consultations. A cohort of patients with similar chief complaints prior to implementation of online consultations was used as a control group (CONTROL). Prospective data from local registries and medical records was gathered 14 days the consultation. The primary outcome was rate of antibiotic prescription after sore throat. Secondary outcomes included patient revisits (including hospital admissions), patient satisfaction, time to physician contact, registered diagnosis, and documentation or Centor Criteria and Urinary Tract Infection (UTI)-Criteria. SIGNIFICANCE: Results will shed light on whether antibiotic prescription differs significantly between digital and physical primary care consultations. Hypotheses may also be generated as to how patients seek care in light of improved availability in a tax-sponsored healthcare system.
Status | Completed |
Enrollment | 4057 |
Est. completion date | December 20, 2021 |
Est. primary completion date | December 6, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient seeking care at primary healthcare provider (Capio in Skåne or Capio Go) - Patient who according to medical record presents with sore throat, cough/common cold/influenza, or dysuria Exclusion Criteria: - Patient who according to medical record presents with main symptom other than sore throat, cough/common cold/influenza, or dysuria. - Patient under the age of 18. |
Country | Name | City | State |
---|---|---|---|
Sweden | Capio Go | Malmö |
Lead Sponsor | Collaborator |
---|---|
Region Skane | Capio Go, Capio Group, Doctrin, Lund University |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Antibiotics Prescription After Sore Throat | Proportion of patients prescribed an antibiotics (as documented in medical records) in conjunction with their initial visit with chief complaint sore throat. | 24 hours | |
Secondary | Antibiotics Prescription After Cough/Common Cold/Influenza | Proportion of patients prescribed an antibiotics (as documented in medical records) in conjunction with their initial visit with chief complaint cough/common cold/influenza. | 24 hours | |
Secondary | Antibiotics Prescription After Dysuria | Proportion of patients prescribed an antibiotics (as documented in medical records) in conjunction with their initial visit with chief complaint dysuria. | 24 hours | |
Secondary | Patient Revisits | Number of healthcare-system visits following initial consultation (as documented in local registries). Includes outpatient as well as inpatient visits. | 14 days | |
Secondary | Type of Antibiotic Prescribed | ATC-codes of antibiotics prescribed in conjunction with the initial consultation. | 24 hours | |
Secondary | Registered Diagnosis | Diagnosis registered in with medical journal in conjunction with with initial consultation. | 24 hours | |
Secondary | Patient Satisfaction | Average scores documented on a 3 question survey, if documented. | 24 hours | |
Secondary | Time to Physician Contact | DIGI: Time from patient log-in on the online platform to first speech-bubble from the physician.
PHYSI and CONTROL: Time from registered telephone contact to registered physician contact. |
14 days | |
Secondary | Centor Criteria Documentation | Proportion of patients where Centor Criteria are fully documented in the medical record in conjunction with the initial consultation.
Centor criteria: Tonsillar redness/exudates, Tender anterior cervical adenopathy, fever over 38,5° C, absence of cough. |
24 hours | |
Secondary | UTI Criteria Documentation | Proportion of patients where urinary tract infection criteria are fully documented in the medical record in conjunction with the initial consultation.
UTI Criteria: increased pain, frequency, urgency. Lack of vaginal symptoms, fever or flank pain. |
24 hours | |
Secondary | Ordering of labs for sore throat | Defined as "StrepA" quick-test for group A Streptococcus (GAS)-tonsillitis, including outcome | 24 hours | |
Secondary | Ordering of labs for dysuria | Defined as urinalysis, including outcomes of leukocytes and nitrate | 24 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |